Endometrial morphology during hormone replacement therapy with @entity53 gel combined to @entity2692 -releasing intrauterine device or natural XXXX .

@entity1 @entity172 @entity1420 @entity1373 @entity2692 @entity53 @entity3202 @entity194 @entity2588
OBJECTIVES: To evaluate endometrial responses to three different forms of @entity2588 -inducing HRT in postmenopausal @entity1 . MATERIAL AND METHODS: Fifty-one postmenopausal @entity1 completing a one-year HRT trial with percutaneous @entity53 gel containing 1.5 mg @entity53 daily combined with a @entity2692 -releasing intrauterine device (LNG-IUD) (n=18), or natural @entity1420 100 mg daily orally (n= 19) or vaginally (n=15) during 1-25 calendar days of each month. Endometrial thickness and uterine size were measured by transvaginal ultrasound, and endometrial cytology/histology was assessed from specimens taken by needle aspiration before the study and at 12 months. RESULTS: Before medication, the median endometrial thickness was 2.0 mm in the LNG-IUD group, 2.4 mm in the oral P group and 2.5 mm in the vaginal P group. At 12 months of therapy the respective values, 3.0, 2.7 and 2.4 mm, did not differ significantly from the initial values. LNG-IUD induced @entity194 in all @entity1 , which was accompanied by stromal decidualization in 12 @entity1 . On the contrary, only four @entity1 in the oral P group and five @entity1 in the vaginal P group had an inactive or @entity3202 endometrium. The remaining cases were dominated by proliferative features. No @entity1373 was seen in any of the groups. CONCLUSION: LNG-IUD appeared to be an effective method of counteracting the stimulatory effect of @entity172 on the endometrium, whereas natural @entity1420 given orally or vaginally was not sufficiently effective in this function at the doses used. The vaginal and oral administrations of @entity1420 did not differ from each other in this respect.
